Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity.

已完结 10 由 Tsui 发布于 2026/3/27 15:41:01

DOI:10.1136/gutjnl-2025-337780
作者：Lei Xiong,Jianshang Huang,Yunsheng Dong,Wei Han,Wei-Ting Kuo,Wentao Xu,Yiran Han,Chenchen An,Rumeng Zhu,Nina Zhu,Hanqi Xia,Abduxukur Rahman,Sainan Tang,Chonggui Jiang,Junhao Zhao,Wangxiang Pei,Juan Wa
文献类型：期刊论文
补充材料：只需要正文

BMJ

Abstract：OBJECTIVE Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment and patients' survival. However, ICIs also cause severe immune-related adverse events, notably colitis, re

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierA new deep eutectic solvent based on diphenylguanidine for the effective extraction of pertechnetate anion